Loading...
Otsuka Holdings Co., Ltd.
OTSKY•PNK
Healthcare
Drug Manufacturers - General
$25.01
$1.31(5.53%)
Otsuka Holdings Co., Ltd. (OTSKY) Financial Performance & Income Statement Overview
Review Otsuka Holdings Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
15.42%
↑ 15.42%
Operating Income Growth
131.76%
↑ 131.76%
Net Income Growth
182.13%
↑ 182.13%
Operating Cash Flow Growth
25.21%
↑ 25.21%
Operating Margin
14.92%
↑ 14.92%
Gross Margin
70.76%
↑ 70.76%
Net Profit Margin
4.11%
↑ 4.11%
ROE
2.70%
↑ 2.70%
ROIC
8.37%
↑ 8.37%
Otsuka Holdings Co., Ltd. (OTSKY) Income Statement & Financial Overview
Review Otsuka Holdings Co., Ltd.'s (OTSKY) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $582.84B | $599.78B | $621.15B | $589.41B |
| Cost of Revenue | $156.65B | $177.69B | $166.53B | $164.41B |
| Gross Profit | $426.19B | $422.09B | $454.62B | $425.003B |
| Gross Profit Ratio | $0.73 | $0.70 | $0.73 | $0.72 |
| R&D Expenses | $78.38B | $91.25B | $76.20B | $71.56B |
| SG&A Expenses | $232.50B | $265.12B | $241.33B | $239.97B |
| Operating Expenses | $310.88B | $359.57B | $317.53B | $311.53B |
| Total Costs & Expenses | $467.52B | $537.27B | $484.06B | $475.94B |
| Interest Income | $2.69B | $0.00 | $0.00 | $10.49B |
| Interest Expense | $13.74B | $0.00 | $8.89B | $2.63B |
| Depreciation & Amortization | $27.14B | $27.56B | $27.02B | $27.34B |
| EBITDA | $146.62B | $90.62B | $138.48B | $154.36B |
| EBITDA Ratio | $0.25 | $0.15 | $0.22 | $0.26 |
| Operating Income | $115.32B | $62.52B | $137.09B | $113.47B |
| Operating Income Ratio | $0.20 | $0.10 | $0.22 | $0.19 |
| Other Income/Expenses (Net) | -$9.58B | $17.32B | -$34.51B | $7.86B |
| Income Before Tax | $105.73B | $79.84B | $102.58B | $30.93B |
| Income Before Tax Ratio | $0.18 | $0.13 | $0.17 | $0.05 |
| Income Tax Expense | $27.40B | -$72.45B | $29.46B | $10.39B |
| Net Income | $85.00B | $151.45B | $83.88B | $30.42B |
| Net Income Ratio | $0.15 | $0.25 | $0.14 | $0.05 |
| EPS | $158.57 | $281.40 | $154.71 | $56.04 |
| Diluted EPS | $158.57 | $281.40 | $154.71 | $56.04 |
| Weighted Avg Shares Outstanding | $536.01M | $538.20M | $542.14M | $542.80M |
| Weighted Avg Shares Outstanding (Diluted) | $536.01M | $538.20M | $542.14M | $542.80M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan